Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation. Issue 2 (28th January 2020)

• Record Type: Journal Article
• Authors: Yang, Fei; Yang, Xiaodong; Bao, Xiebing; Kang, Liqing; Zhou, Lili; Wu, Xiaoxia; Tang, Xiaowen; Fu, Zhengzheng; Ma, Xiao; Sun, Aining; Zhang, Jian; Qiu, Huiying; Wu, Deipei
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 2(2020)
• Page Start: 429
• Page End: 436
• Publication Date: 2020-01-28
• Subjects: CD19 -- chimeric antigen receptor T-cells -- Philadelphia -- acute lymphoblastic leukemia -- T315I mutation -- Ponatinib; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1663417
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Effective treatments for relapsed Ph + ALL with T315I mutation are few; CD19 CAR T-cell therapy are a potential therapy for this condition. We reported 7 patients with relapsed Ph + ALL with T315I mutation, who were treated pre- or post-allo-HSCT with CD19-specific CAR T-cells. Of the 7 cases, 6 were in CR or CRp within 1 month after the first infusion of CAR T-cells. MRD revealed a rapid decline in 6 patients. BCR/ABL fusion transcripts were negative in 4/5 cases (not performed in 2). Three patients maintained remission without evidence of MRD by QPCR until the final follow-up, of which 2 received anti-CD19 CAR T-cells and ponatinib at the same time. Our study confirmed the efficacy of anti-CD19 CAR T-cell therapy in treatment of relapsed Ph + ALL with T315I mutation pre- or post-allo-HSCT and the concurrent applicability of this therapy with ponatinib.